Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antisense Oligonucleotides
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Cancer Institute
Deal Size : $0.4 million
Deal Type : Funding
Details : AUM LifeTech's FANA Antisense Oligonucleotide (FANA ASO) RNA silencing approach allows efficient and selective targeting of human FOXP3 at the RNA level, in a highly sequence-specific manner.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 17, 2022
Lead Product(s) : Antisense Oligonucleotides
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Cancer Institute
Deal Size : $0.4 million
Deal Type : Funding
Lead Product(s) : Anitisense Oligonucleotides
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AUM LifeTech Present Preclinical Data on Lung Cancer, PD, and HIV at BIO Digital
Details : AUM LifeTech has developed their preclinical pipeline in cancer immunotherapy with a focus on lung cancer using their proprietary RNA targeting technology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 10, 2021
Lead Product(s) : Anitisense Oligonucleotides
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?